RG
DNTH icon

Rathbones Group’s Dianthus Therapeutics DNTH Stock Holding History

Rathbones Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-625
Closed -$7.58K – 635
2023
Q2 		$7.58K Hold
625
– – ﹤0.01% 409
2023
Q1 		$7.95K Hold
625
– – ﹤0.01% 412
2022
Q4 		$3.95K Hold
625
– – ﹤0.01% 422
2022
Q3 		$14K Hold
625
– – ﹤0.01% 414
2022
Q2 		$12K Buy
+625
New +$15.4K ﹤0.01% 427

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Rathbones Group's DNTH Position: Q3 2023 in Review

Rathbones Group sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 625 shares — an estimated $7.58K sold.

Rathbones Group first reported a position in DNTH in Q2 2022 and held it in 5 quarters. The position peaked at $14K in Q3 2022. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

  • Rathbones Group reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Rathbones Group sold 625 Dianthus Therapeutics shares in Q3 2023, an estimated $7.58K.
  • Rathbones Group first reported a position in Dianthus Therapeutics in Q2 2022 and held it in 5 quarters.
  • Rathbones Group's Dianthus Therapeutics position peaked at $14K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Rathbones Group's 13F filing for Q3 2023, filed 13 Nov 2023.